The U.S. Food and Drug Administration has approved SPEVIGO (spesolimab-sbzo) as the first treatment option for generalized pustular psoriasis (GPP) flares in adults.
This article was originally published on MedicalXpress.com
The U.S. Food and Drug Administration has approved SPEVIGO (spesolimab-sbzo) as the first treatment option for generalized pustular psoriasis (GPP) flares in adults.
This article was originally published on MedicalXpress.com
Lyme disease is a tick-born infection caused by bacteria known as Borrelia burgdorferi. Lyme carditis is an early manifestation of Lyme disease that can occur two to six weeks after the tick bite. Approximately five to 10 per […]
Early-onset colorectal cancer incidence among the young, defined as those under age 50, has been rising globally since the early 1990s. Rates for colon and rectal cancers are expected to increase by 90% and 124%, respectively, by 2030. […]
The COVID-19 pandemic has shed light on the precarious living conditions of the elderly in nursing homes in Canada. During the first wave of the pandemic, from March to August 2020, more than 80 per […]
© 2023 SimplyWell.ca